The other treatment is based on combined MEK and BCL-XL blockage (MEKi+BCL-XLi), a synthetic lethal interaction we uncovered on a panel of human/mouse HCC cells and demonstrated to be effective in vivo,26,33 which has been reported also in other cancer types.34 Here, BCL2L1 is linked to hepatocellular carcinoma.